HRP20030053A2 - Novel compounds and their use as glycine transport inhibitors - Google Patents
Novel compounds and their use as glycine transport inhibitors Download PDFInfo
- Publication number
- HRP20030053A2 HRP20030053A2 HR20030053A HRP20030053A HRP20030053A2 HR P20030053 A2 HRP20030053 A2 HR P20030053A2 HR 20030053 A HR20030053 A HR 20030053A HR P20030053 A HRP20030053 A HR P20030053A HR P20030053 A2 HRP20030053 A2 HR P20030053A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- phenyl
- propyl
- independently represent
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 41
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title description 22
- 239000004471 Glycine Substances 0.000 title description 13
- 239000003112 inhibitor Substances 0.000 title description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 claims description 13
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000004810 Vascular dementia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000037410 cognitive enhancement Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229960002449 glycine Drugs 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- -1 phencyclidine Chemical class 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- CDVLPBUKUVKVBA-UEDXYCIISA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]propanoic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 CDVLPBUKUVKVBA-UEDXYCIISA-N 0.000 description 3
- RBAQCYGDDPOWCE-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C)C=C1 RBAQCYGDDPOWCE-UHFFFAOYSA-N 0.000 description 3
- PFUNWACYBDHFAL-UHFFFAOYSA-N 2-[3-[5-bromo-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Br)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 PFUNWACYBDHFAL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KEIDEHNAVGKQCB-NVHKAFQKSA-N (2s)-2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]propanoic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KEIDEHNAVGKQCB-NVHKAFQKSA-N 0.000 description 2
- AQFYBBOVSHVEKK-CPFIQGLUSA-N (2s)-2-[3-[1-(4-chlorophenyl)-3,3-diethyl-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 AQFYBBOVSHVEKK-CPFIQGLUSA-N 0.000 description 2
- BLRLFAJWSBAXFC-YXWRBFHGSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 BLRLFAJWSBAXFC-YXWRBFHGSA-N 0.000 description 2
- BDLPQYZTXBBTQE-YPHUNTSASA-N (2s)-2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]propanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 BDLPQYZTXBBTQE-YPHUNTSASA-N 0.000 description 2
- XKOQVRLECUULHT-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 XKOQVRLECUULHT-UHFFFAOYSA-N 0.000 description 2
- CIWXIAJJCJIWOE-UHFFFAOYSA-N 2-[2-[1-(4-chlorophenyl)-5-(5-chlorothiophen-2-yl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)S1 CIWXIAJJCJIWOE-UHFFFAOYSA-N 0.000 description 2
- SHIGDERHWRPXFW-UHFFFAOYSA-N 2-[3-[1,5-bis(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)C=C1 SHIGDERHWRPXFW-UHFFFAOYSA-N 0.000 description 2
- SPHUZYRFLZYOHP-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC(Cl)=CC=C1Cl SPHUZYRFLZYOHP-UHFFFAOYSA-N 0.000 description 2
- PIUPRVAVNBKRAQ-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(2-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C PIUPRVAVNBKRAQ-UHFFFAOYSA-N 0.000 description 2
- JMZRXZUYTKWUCL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(Cl)C(Cl)=C1 JMZRXZUYTKWUCL-UHFFFAOYSA-N 0.000 description 2
- OUFAHQPFGFOCCL-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C)=C1 OUFAHQPFGFOCCL-UHFFFAOYSA-N 0.000 description 2
- OEEPPXCUYXQRLI-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C2C(C=3C=CC(Cl)=CC=3)(CCCN(C)CC(O)=O)OCC2=C1 OEEPPXCUYXQRLI-UHFFFAOYSA-N 0.000 description 2
- TXGJKJXYOREALM-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC(C(F)(F)F)=C1 TXGJKJXYOREALM-UHFFFAOYSA-N 0.000 description 2
- JUWVFZAPYCYAKO-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[4-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=C(C(F)(F)F)C=C1 JUWVFZAPYCYAKO-UHFFFAOYSA-N 0.000 description 2
- RTWGCBZBZKLFHN-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 RTWGCBZBZKLFHN-UHFFFAOYSA-N 0.000 description 2
- YERIVNORZKQTBA-UHFFFAOYSA-N 2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]acetic acid Chemical compound C1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 YERIVNORZKQTBA-UHFFFAOYSA-N 0.000 description 2
- CYKZSTVLKQCCOE-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 CYKZSTVLKQCCOE-UHFFFAOYSA-N 0.000 description 2
- BYEFBPYBYKBWFR-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BYEFBPYBYKBWFR-UHFFFAOYSA-N 0.000 description 2
- ZFKXLIIUEFDRBB-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(C#N)C=C2CO1 ZFKXLIIUEFDRBB-UHFFFAOYSA-N 0.000 description 2
- BQAUJJODONZZMO-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 BQAUJJODONZZMO-UHFFFAOYSA-N 0.000 description 2
- FPZVLWDUJCYRDE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 FPZVLWDUJCYRDE-UHFFFAOYSA-N 0.000 description 2
- GXOOUMOOGHJCHS-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenylinden-1-yl)propyl]amino]acetic acid Chemical compound C1=C(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 GXOOUMOOGHJCHS-UHFFFAOYSA-N 0.000 description 2
- HYHCUOXXBRKVIT-UHFFFAOYSA-N 2-[methyl-[3-[1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 HYHCUOXXBRKVIT-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 description 2
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- OSVAYUPHKDNSKR-UHFFFAOYSA-N ethyl 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetate Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(=O)OCC)C1=CC=C(F)C=C1 OSVAYUPHKDNSKR-UHFFFAOYSA-N 0.000 description 2
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- RLMHMDMIOFCETG-UBDBMELISA-N (2s)-2-[3-(3,3-diethyl-1-phenyl-2-benzofuran-1-yl)propyl-methylamino]propanoic acid Chemical compound C12=CC=CC=C2C(CC)(CC)OC1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 RLMHMDMIOFCETG-UBDBMELISA-N 0.000 description 1
- TTXZKKPKXJFPSV-YTJLLHSVSA-N (2s)-2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CS1 TTXZKKPKXJFPSV-YTJLLHSVSA-N 0.000 description 1
- BQJWQOOWJOBXGB-ZDGMYTEDSA-N (2s)-2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 BQJWQOOWJOBXGB-ZDGMYTEDSA-N 0.000 description 1
- OCAHTDRUXVBMOW-MXMOWUBCSA-N (2s)-2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 OCAHTDRUXVBMOW-MXMOWUBCSA-N 0.000 description 1
- UAUWLEHSOZBEQW-YXWRBFHGSA-N (2s)-2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 UAUWLEHSOZBEQW-YXWRBFHGSA-N 0.000 description 1
- SXTQZBWYMOQNCU-VYTWEFSNSA-N (2s)-2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(F)C=C1 SXTQZBWYMOQNCU-VYTWEFSNSA-N 0.000 description 1
- JSHPGKFTWNDYTC-JQVYNXHMSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.C1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 JSHPGKFTWNDYTC-JQVYNXHMSA-N 0.000 description 1
- NNMDLTSDCPVATO-VYTWEFSNSA-N (2s)-2-[3-[5-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC(Cl)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(Cl)C=C1 NNMDLTSDCPVATO-VYTWEFSNSA-N 0.000 description 1
- QNZUEKRUUYXCNU-GZWBLTSWSA-N (2s)-2-[3-[5-cyano-1-(4-cyanophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]propanoic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=C(C#N)C=C1 QNZUEKRUUYXCNU-GZWBLTSWSA-N 0.000 description 1
- TUKYQPWIBZTOSR-BJQOMGFOSA-N (2s)-2-[methyl-[3-(1-phenyl-3h-2-benzothiophen-1-yl)propyl]amino]propanoic acid Chemical compound S1CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 TUKYQPWIBZTOSR-BJQOMGFOSA-N 0.000 description 1
- KKNQZVJEWPHXIG-LBOXEOMUSA-N (2s)-2-[methyl-[3-(1-phenylinden-1-yl)propyl]amino]propanoic acid Chemical compound C1=CC2=CC=CC=C2C1(CCCN(C)[C@@H](C)C(O)=O)C1=CC=CC=C1 KKNQZVJEWPHXIG-LBOXEOMUSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- UORHYDOYNNNDHW-UHFFFAOYSA-N 1-(4-fluorophenyl)-1-(3-iodopropyl)-3h-2-benzofuran-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(CCCI)C2=CC=C(C#N)C=C2CO1 UORHYDOYNNNDHW-UHFFFAOYSA-N 0.000 description 1
- SCTGAEHVEUYYGU-UHFFFAOYSA-N 2-[2-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(F)C=C1 SCTGAEHVEUYYGU-UHFFFAOYSA-N 0.000 description 1
- PXPLWZYFONHMMS-UHFFFAOYSA-N 2-[2-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]ethyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCN(C)CC(O)=O)C1=CC=C(F)C=C1 PXPLWZYFONHMMS-UHFFFAOYSA-N 0.000 description 1
- HOKCJTQMQWEJBK-UHFFFAOYSA-N 2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]acetic acid Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 HOKCJTQMQWEJBK-UHFFFAOYSA-N 0.000 description 1
- JEAKOGHXLPESQX-UHFFFAOYSA-N 2-[3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.S1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC=C1 JEAKOGHXLPESQX-UHFFFAOYSA-N 0.000 description 1
- MMEFKIFIMMDSTF-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]acetic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CS1 MMEFKIFIMMDSTF-UHFFFAOYSA-N 0.000 description 1
- RQHGELJFTUQRGZ-UHFFFAOYSA-N 2-[3-(5-chloro-1-thiophen-2-yl-3h-2-benzofuran-1-yl)propyl-methylamino]butanoic acid Chemical compound O1CC2=CC(Cl)=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CS1 RQHGELJFTUQRGZ-UHFFFAOYSA-N 0.000 description 1
- SQWYCLPSDYACTO-UHFFFAOYSA-N 2-[3-[1-(3-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(Cl)=C1 SQWYCLPSDYACTO-UHFFFAOYSA-N 0.000 description 1
- IIRRRHJJKOOZJJ-UHFFFAOYSA-N 2-[3-[1-(3-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(Cl)=C1 IIRRRHJJKOOZJJ-UHFFFAOYSA-N 0.000 description 1
- KGPQQENJOWEIII-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-3,3-dimethyl-2h-inden-1-yl]propyl-methylamino]acetic acid Chemical compound C1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 KGPQQENJOWEIII-UHFFFAOYSA-N 0.000 description 1
- KAPQYVCDDXBUIY-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-[2-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(Cl)=CC=3)OCC2=CC=1C1=CC=CC=C1C(F)(F)F KAPQYVCDDXBUIY-UHFFFAOYSA-N 0.000 description 1
- LTSWUMKWZXTGOB-UHFFFAOYSA-N 2-[3-[1-(4-chlorophenyl)-5-fluoro-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 LTSWUMKWZXTGOB-UHFFFAOYSA-N 0.000 description 1
- ZLOHYHCNWKILRP-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3,3-dimethyl-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 ZLOHYHCNWKILRP-UHFFFAOYSA-N 0.000 description 1
- BKZQAANJGUQRNB-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 BKZQAANJGUQRNB-UHFFFAOYSA-N 0.000 description 1
- YBKWCNOLXLQXGL-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 YBKWCNOLXLQXGL-UHFFFAOYSA-N 0.000 description 1
- WKFMECNVGHSJRN-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]butanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=C(F)C=C1 WKFMECNVGHSJRN-UHFFFAOYSA-N 0.000 description 1
- HPGIDFCZZZSUNU-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 HPGIDFCZZZSUNU-UHFFFAOYSA-N 0.000 description 1
- VYPHKMMGJHXGLO-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-(trifluoromethyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C(F)(F)F)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 VYPHKMMGJHXGLO-UHFFFAOYSA-N 0.000 description 1
- ZQQZFRRMHNULQI-UHFFFAOYSA-N 2-[3-[1-(4-fluorophenyl)-5-[4-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C=1C=C2C(CCCN(C)CC(O)=O)(C=3C=CC(F)=CC=3)OCC2=CC=1C1=CC=C(C(F)(F)F)C=C1 ZQQZFRRMHNULQI-UHFFFAOYSA-N 0.000 description 1
- BGASQIGFXFNAQQ-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 BGASQIGFXFNAQQ-UHFFFAOYSA-N 0.000 description 1
- KDETUNZZDAVRHR-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 KDETUNZZDAVRHR-UHFFFAOYSA-N 0.000 description 1
- JNQZCKBPHCADOP-UHFFFAOYSA-N 2-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC(C(=CC=C2)Cl)=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 JNQZCKBPHCADOP-UHFFFAOYSA-N 0.000 description 1
- AZNVOIZXPGYOSB-UHFFFAOYSA-N 2-[3-[5-chloro-1-(4-chlorophenyl)-2,3-dihydroinden-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1CC2=CC(Cl)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 AZNVOIZXPGYOSB-UHFFFAOYSA-N 0.000 description 1
- WKUPMDJWESAHCK-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 WKUPMDJWESAHCK-UHFFFAOYSA-N 0.000 description 1
- LKDQVWXBEMADHF-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC(C#N)=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C=C1 LKDQVWXBEMADHF-UHFFFAOYSA-N 0.000 description 1
- UMOOSINNKYLLDU-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]propylamino]acetic acid Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCNCC(=O)O)C1=CC=C(F)C=C1 UMOOSINNKYLLDU-UHFFFAOYSA-N 0.000 description 1
- VWFCLAZEBNWWKY-UHFFFAOYSA-N 2-[3-[5-cyano-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(C#N)C=C2CO1 VWFCLAZEBNWWKY-UHFFFAOYSA-N 0.000 description 1
- WINGQRZUAIJHKN-UHFFFAOYSA-N 2-[3-[5-fluoro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC=C(F)C=C2CO1 WINGQRZUAIJHKN-UHFFFAOYSA-N 0.000 description 1
- GIUHFAPURGBVFT-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-chlorophenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(Cl)C=C1 GIUHFAPURGBVFT-UHFFFAOYSA-N 0.000 description 1
- JVQZDCZIFSRDQU-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-fluoro-3-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(F)C(C)=C1 JVQZDCZIFSRDQU-UHFFFAOYSA-N 0.000 description 1
- FQMHYNZGTKQLBE-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC(Cl)=CC=C2CO1 FQMHYNZGTKQLBE-UHFFFAOYSA-N 0.000 description 1
- ODHVKYXAEWWGCM-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methoxyphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1(CCCN(C)CC(O)=O)C2=CC(Cl)=CC=C2CO1 ODHVKYXAEWWGCM-UHFFFAOYSA-N 0.000 description 1
- AXADURWEISCUSH-UHFFFAOYSA-N 2-[3-[6-chloro-1-(4-methylphenyl)-3h-2-benzofuran-1-yl]propyl-methylamino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=C(Cl)C=C2C1(CCCN(C)CC(O)=O)C1=CC=C(C)C=C1 AXADURWEISCUSH-UHFFFAOYSA-N 0.000 description 1
- CEETWSDATDRVAC-UHFFFAOYSA-N 2-[methyl-[3-(3-methyl-1-phenyl-3h-2-benzofuran-1-yl)propyl]amino]butanoic acid Chemical compound O1C(C)C2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC=C1 CEETWSDATDRVAC-UHFFFAOYSA-N 0.000 description 1
- FWMFQNAGGJQHLP-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]acetic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(C(F)(F)F)=C1 FWMFQNAGGJQHLP-UHFFFAOYSA-N 0.000 description 1
- UXYJEJXEISGCGB-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]acetic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)CC(O)=O)C1=CC=CC(C(F)(F)F)=C1 UXYJEJXEISGCGB-UHFFFAOYSA-N 0.000 description 1
- WRMMTIZXXADKOG-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]butanoic acid Chemical compound O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC(C(F)(F)F)=C1 WRMMTIZXXADKOG-UHFFFAOYSA-N 0.000 description 1
- AZLJECUPHBHYQD-UHFFFAOYSA-N 2-[methyl-[3-[1-[3-(trifluoromethyl)phenyl]-3h-2-benzofuran-1-yl]propyl]amino]butanoic acid;hydrochloride Chemical compound Cl.O1CC2=CC=CC=C2C1(CCCN(C)C(CC)C(O)=O)C1=CC=CC(C(F)(F)F)=C1 AZLJECUPHBHYQD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FDXBTCYDTGBJLN-UHFFFAOYSA-N Cl.CC1=CC=C(C=C1)C1(OCC2=CC=CC=C12)CCCN(CC(=O)O)C Chemical compound Cl.CC1=CC=C(C=C1)C1(OCC2=CC=CC=C12)CCCN(CC(=O)O)C FDXBTCYDTGBJLN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000220304 Prunus dulcis Species 0.000 description 1
- 102100028886 Sodium- and chloride-dependent glycine transporter 2 Human genes 0.000 description 1
- 101710083167 Sodium- and chloride-dependent glycine transporter 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- BTKSUULMJNNXHG-UHFFFAOYSA-N ethyl 2-(methylamino)acetate Chemical compound CCOC(=O)CNC BTKSUULMJNNXHG-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical class Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001124 | 2000-07-21 | ||
PCT/DK2001/000510 WO2002008216A1 (en) | 2000-07-21 | 2001-07-19 | Novel compounds and their use as glycine transport inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030053A2 true HRP20030053A2 (en) | 2005-02-28 |
Family
ID=8159626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030053A HRP20030053A2 (en) | 2000-07-21 | 2003-01-27 | Novel compounds and their use as glycine transport inhibitors |
Country Status (28)
Country | Link |
---|---|
US (1) | US6921774B2 (pt) |
EP (1) | EP1301502B1 (pt) |
JP (1) | JP2004504393A (pt) |
KR (1) | KR20030015889A (pt) |
CN (1) | CN100509791C (pt) |
AR (1) | AR032358A1 (pt) |
AT (1) | ATE295844T1 (pt) |
AU (2) | AU8174001A (pt) |
BG (1) | BG107530A (pt) |
BR (1) | BR0113011A (pt) |
CA (1) | CA2416447A1 (pt) |
CZ (1) | CZ2003396A3 (pt) |
DE (1) | DE60110914T2 (pt) |
EA (1) | EA005621B1 (pt) |
ES (1) | ES2238466T3 (pt) |
HR (1) | HRP20030053A2 (pt) |
HU (1) | HUP0302778A3 (pt) |
IL (2) | IL153988A0 (pt) |
IS (1) | IS6693A (pt) |
MX (1) | MXPA03000642A (pt) |
NO (1) | NO20030243L (pt) |
NZ (1) | NZ523720A (pt) |
PL (1) | PL364439A1 (pt) |
PT (1) | PT1301502E (pt) |
SK (1) | SK2022003A3 (pt) |
UA (1) | UA75081C2 (pt) |
WO (1) | WO2002008216A1 (pt) |
ZA (1) | ZA200300514B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060004967A (ko) * | 2003-04-30 | 2006-01-16 | 하. 룬트벡 아크티에 셀스카브 | 방향족 옥시페닐 및 방향족 설파닐페닐 유도체 |
CN1867358A (zh) * | 2003-08-21 | 2006-11-22 | H.隆德贝克有限公司 | 用于治疗抑郁症的5-羟色胺再摄取抑制剂和1型甘氨酸转运蛋白抑制剂的联合药物 |
US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
JP2007528879A (ja) * | 2004-03-12 | 2007-10-18 | ハー・ルンドベック・アクチエゼルスカベット | フェニルインダン誘導体 |
WO2005100301A1 (en) * | 2004-03-31 | 2005-10-27 | Eli Lilly And Company | 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors |
WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
JP5109974B2 (ja) * | 2006-07-18 | 2012-12-26 | アステラス製薬株式会社 | アミノインダン誘導体又はその塩 |
ES2392105T3 (es) * | 2006-08-30 | 2012-12-04 | F. Hoffmann-La Roche Ag | Inhibidores de GlyT-1 |
US20100083581A1 (en) * | 2007-06-18 | 2010-04-08 | Mattice Douglas A | Environmental brush seal |
EP2389187B1 (en) | 2009-01-20 | 2016-11-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
US9700563B2 (en) * | 2012-09-06 | 2017-07-11 | MediSynergies, LLC | Kappa opioid receptor compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1166711A (en) * | 1966-03-28 | 1969-10-08 | Kefalas As | Process for the Preparation of Phenyl-Indane and -Tetralin Derivatives |
US3549656A (en) * | 1967-12-28 | 1970-12-22 | Kefalas As | Antidepressant 1 - aminoalkyl - thiophthalanes and acid addition salts thereof |
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
US5225323A (en) | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
CA2123323A1 (en) | 1991-11-12 | 1993-05-27 | Neurogenetic Corporation | Dna encoding a glycine transporter and uses thereof |
US5824486A (en) | 1996-05-31 | 1998-10-20 | Allelix Neuroscience Inc. | Glycine transporter-transfected cells and uses thereof |
US6008015A (en) | 1997-04-11 | 1999-12-28 | Allelix Neuroscience Inc. | Glycine transporter |
AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6566550B2 (en) * | 2001-06-21 | 2003-05-20 | Pfizer Inc | Substituted aromatic ethers as inhibitors of glycine transport |
-
2001
- 2001-07-19 DE DE60110914T patent/DE60110914T2/de not_active Expired - Fee Related
- 2001-07-19 WO PCT/DK2001/000510 patent/WO2002008216A1/en not_active Application Discontinuation
- 2001-07-19 EA EA200300180A patent/EA005621B1/ru not_active IP Right Cessation
- 2001-07-19 CA CA002416447A patent/CA2416447A1/en not_active Abandoned
- 2001-07-19 CN CNB018158579A patent/CN100509791C/zh not_active Expired - Fee Related
- 2001-07-19 UA UA2003010452A patent/UA75081C2/uk unknown
- 2001-07-19 PT PT01960184T patent/PT1301502E/pt unknown
- 2001-07-19 AU AU8174001A patent/AU8174001A/xx active Pending
- 2001-07-19 KR KR10-2003-7000851A patent/KR20030015889A/ko not_active Application Discontinuation
- 2001-07-19 AU AU2001281740A patent/AU2001281740B2/en not_active Ceased
- 2001-07-19 AT AT01960184T patent/ATE295844T1/de not_active IP Right Cessation
- 2001-07-19 HU HU0302778A patent/HUP0302778A3/hu unknown
- 2001-07-19 MX MXPA03000642A patent/MXPA03000642A/es not_active Application Discontinuation
- 2001-07-19 PL PL01364439A patent/PL364439A1/xx not_active Application Discontinuation
- 2001-07-19 BR BR0113011-0A patent/BR0113011A/pt not_active IP Right Cessation
- 2001-07-19 EP EP01960184A patent/EP1301502B1/en not_active Expired - Lifetime
- 2001-07-19 ES ES01960184T patent/ES2238466T3/es not_active Expired - Lifetime
- 2001-07-19 IL IL15398801A patent/IL153988A0/xx not_active IP Right Cessation
- 2001-07-19 JP JP2002514122A patent/JP2004504393A/ja not_active Withdrawn
- 2001-07-19 CZ CZ2003396A patent/CZ2003396A3/cs unknown
- 2001-07-19 SK SK202-2003A patent/SK2022003A3/sk unknown
- 2001-07-19 NZ NZ523720A patent/NZ523720A/en unknown
- 2001-07-20 AR ARP010103460A patent/AR032358A1/es not_active Application Discontinuation
-
2003
- 2003-01-16 IL IL153988A patent/IL153988A/en unknown
- 2003-01-17 NO NO20030243A patent/NO20030243L/no not_active Application Discontinuation
- 2003-01-17 US US10/348,490 patent/US6921774B2/en not_active Expired - Fee Related
- 2003-01-20 IS IS6693A patent/IS6693A/is unknown
- 2003-01-20 ZA ZA200300514A patent/ZA200300514B/en unknown
- 2003-01-27 HR HR20030053A patent/HRP20030053A2/hr not_active Application Discontinuation
- 2003-02-05 BG BG107530A patent/BG107530A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0655055B1 (en) | Tachykinin antagonists | |
CN102066360B (zh) | 喹啉或异喹啉取代的p2x7拮抗剂 | |
JP2007527363A (ja) | バニロイドvr1受容体のモジュレーターであるキノリン誘導アミド | |
PL167994B1 (pl) | Sposób wytwarzania nowych aryloalkiloamin PL PL PL PL PL PL | |
GB2271774A (en) | Piperazine derivatives | |
HRP20030053A2 (en) | Novel compounds and their use as glycine transport inhibitors | |
SK13532000A3 (sk) | Bicyklo [2.2.1] heptány a príbuzné zlúčeniny, farmaceutické kompozície a spôsoby liečenia na ich báze | |
HRP980106A2 (en) | Atropisomers of 3-aryl-4 (3h)-quinazolinones | |
KR100207876B1 (ko) | 치료학적으로 유용한 2-아미노테트랄린 유도체 | |
AU2005250197A1 (en) | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | |
CA2263284A1 (en) | Tetrahydroisoquinoline derivatives and their pharmaceutical use | |
AU2001281740A1 (en) | Novel compounds and their use as glycine transport inhibitors | |
JP4173912B2 (ja) | ニューロキニンアンタゴニストとしてのピペラジノ誘導体 | |
SK160495A3 (en) | Isoquinoline derivatives as therapeutic agents | |
CA2112490A1 (en) | Diamine derivatives having selective affinity for sigma receptors | |
EP0585116B1 (en) | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | |
US6063964A (en) | 5-hydroxymethyl-2-aminotetralins as cardiovascular agents | |
EP1171416B1 (en) | 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors | |
US5021449A (en) | Organic compounds and their use as pharmaceuticals | |
KR20150090769A (ko) | 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물 | |
WO2005021505A1 (en) | The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20040701 Year of fee payment: 4 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |